<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The identification of KRAS and BRAF mutations as predictive molecular alterations of resistance to EGF receptor monoclonal antibody therapy in <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> have significantly improved the selection of patients more likely to be eligible for the treatment with these targeted agents </plain></SENT>
<SENT sid="1" pm="."><plain>Several methods are available for KRAS and BRAF mutation detection but few studies have compared different techniques, especially in the clinical setting </plain></SENT>
<SENT sid="2" pm="."><plain>In this article, we contextualize the wobble-enhanced amplification refractory mutation sequencing method for the identification of KRAS and BRAF mutations with the other methodologies frequently used for the assessment of these alterations in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, discussing advantages and limitations over other frequently used diagnostic methods </plain></SENT>
</text></document>